Advertisement

Boston molecular imaging agents developer FluoroPharma Inc. has completed its merger with Commercial E Waste Management (CEWM). Following the merger with the shell corporation, the resulting, combined public company, FluoroPharma Medical Inc., raised $3.5 million from a stock sale.

FluoroPharma Medical will focus on developing PET imaging products to detect acute and chronic coronary artery disease and Alzheimer’s disease. It currently has clinical trials underway for two products aimed at myocardial cell activity and inflamed plaques within the coronary arteries.

SOURCE

Advertisement
Advertisement